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Summary. While the overall incidence of venous thrombosis is
1–2 per 1000 per year, it is close to 1% per year in the very old.
The case–fatality rate of thrombosis is high in the elderly,
particularly among those with cancer. The risk of major
hemorrhage during anticoagulant treatment is also strongly
age-dependent, contributing to the vulnerability of the old
patient with thrombosis. From this perspective it is surprising
that far fewer studies into the etiology and treatment of venous
thrombosis have focused on the elderly than on young and
middle-aged patients. In this review we discuss that, while
environmental risk factors, such as immobilization and cancer,
are important causes of thrombosis in the elderly, abnormalities
of the coagulation system are equally, or even more, important
than in young individuals. In addition to a review of the
literature, new data are presented from the MEGA-study.
Thrombosis in the elderly should be a focus of future studies.
Keywords: cancer, elderly, epidemiology, risk factors, venous
thrombosis.
Introduction
As much as children are not small adults, the elderly are not
just old adults. Etiology, diagnosis, prognosis and therapy may
all be different in the elderly compared with young or middle-
aged adults. For several diseases, risk factors have been shown
to have reverse effects in old age, e.g. high serum cholesterol
and hypertension no longer predict mortality among the very
old, and may even have an opposite effect, which has been
named reverse epidemiology [1–4]. Not onlymay risk factors act
differently at various ages, but the results of their effects may
also differ because of the exponential rise in incidence of venous
thrombosis with age. Finally, risk factors may have a different
prevalence in the old than in the young (e.g. immobilization,
cancer and drug use). It is remarkable that while it can easily be
shown that themajority of cases of thrombosis occur in the old,
and a substantial number among the very old, studies into
etiology and management are almost completely restricted to
younger age groups.
In this reviewwe deal with the determinants of thrombosis in
general as well as in the elderly.We discuss the effect of the age-
specific incidence of venous thrombosis, and finally present new
data on the effect of two major risk factor groups, thrombo-
philia and malignancies, in elderly individuals, by analysis of a
substudy of the Multiple Environmental and Genetic Assess-
ment (MEGA) of risk factors for venous thrombosis.
Thrombosis
Thrombosis is the formation of obstructive clots in arteries or
veins, because of an inbalance of procoagulant, anticoagulant
and fibrinolytic factors. In venous thrombosis a clot is formed
in reaction to risk factors that are often acute and transient.
Then the clot grows and may cause symptoms suddenly or,
more often, after a period of several days to weeks.
Probably because of its association with sudden and
transient risk factors, rather than insidious factors promoting
slowly accumulating atherosclerosis, knowledge of the etiology
of venous thrombosis preceded by far that of arterial disease:
pregnancy and puerperium were recognized as determinants of
venous thrombosis centuries ago, cancer in the mid-19th
century, and the hereditary nature of venous thrombosis in the
early 1900s [5–8]. The causes of thrombosis were first
categorized by Virchow, who in the mid-1800s postulated
three general causes: changes in the vessel wall, changes in the
blood flow, and changes in the blood composition [9]. Whereas
for arterial disease, vessel wall changes (atherosclerosis) are by
far the most important, in venous thrombosis stasis and
hypercoagulability lead to clot formation and disease.
Venous thrombosis is a common disorder with a frequency
of one to three individuals per 1000 per year [10–14]. It
commonly appears as superficial or deep vein thrombosis of the
leg and pulmonary embolism, and rarely in other locations
(upper extremities, liver, cerebral sinus, retina, mesenteric).
Venous thrombosis occurs about equally often in men and
women, with higher rates among young women than men
because of risk factors associated with reproduction (preg-
nancy, puerperium, oral contraceptives) [13–15]. The post-
thrombotic syndrome occurring in 20% of patients with deep
vein thrombosis may lead to a chronic handicap [16]. One to
Correspondence: F. R. Rosendaal, Departments of Clinical Epide-
miology and Hematology, C9-P, Leiden UniversityMedical Center, PO
Box 9600, NL-2300 RC, Leiden, The Netherlands.
Tel.:+31 71 5264037; fax:+31 71 5266994; e-mail: f.r.rosendaal@
lumc.nl
Received 21 February 2007, accepted 22 February 2007
Journal of Thrombosis and Haemostasis, 5 (Suppl. 1): 310–317
 2007 International Society on Thrombosis and Haemostasis
ten per cent of venous thromboses proves fatal, with the highest
risk of death in those with underlying malignancies [11,13].
Risk of thrombosis in the elderly
The incidence of venous thrombosis is strongly age-dependent:
it is extremely uncommon (1 in 100 000 per year) in childhood,
and rises to nearly 1% per year in very old age [12–15]. Table 1
shows the incidence of venous thrombosis among those aged
65 years and older as found in three large recent studies: a
community-based study from western France, a cohort study
from several sites in the USA (Cardiovascular Health Study),
and a very large population-based study from North-Trønde-
lag in Norway [12,14,17]. The incidences are quite similar, at 3–
4 per 1000 per year. As all three studies applied established
criteria for thrombosis diagnosis, these estimates may be
considered reliable, although cases of fatal pulmonary embo-
lism may have been missed. The slightly lower estimates from
the Cardiovascular Health Study may be due to self-selection
of individuals for a cohort study that includes an intensive
baseline examination, which may lead to an under-representa-
tion of those with morbid conditions (e.g. malignancies). For
studies on a dynamic population, however, it may be difficult to
completely exclude cases with a personal history of thrombosis,
thus inflating the estimates.
Whereas the French study showed little difference in the
incidences between elderly men and women, both the US and
Norwegian studies showed a higher risk for elderly men than
women, which was pronounced in the US study, but only
modest in the much larger study from Norway (Fig. 1).
The incidence of venous thrombosis is< 1 per 1000 per year
up to age 50, and then increases rapidly and exponentially
(Fig. 1). This has major implications for the age distribution of
the patient population with thrombosis, as well as for the effect
of risk factors. From the rates of the Norwegian study, the age
distribution of patients diagnosed with venous thrombosis can
be calculated (Fig. 2) [14] (http://statline.cbs.nl.). This shows
that nearly 70% of all patients diagnosed with venous
thrombosis are over 60, and nearly 25% are over 80 years
old. From this perspective, it is astounding that very few studies
have focused on the elderly and that many have specifically
focused on young patients, for instance in the context of
thrombophilia. It follows from these figures that risk factors
may have vastly different effects among the elderly than among
the young. For instance, a risk factor that quadruples the risk
of venous thrombosis among the young, and doubles the risk
among older individuals, causes far more additional cases of
thrombosis in the older than in the younger age-groups. These
are the relative risks associated with exogenous female
hormone use, either as a contraceptive among young women,
or as hormonal replacement therapy among older women [18–
24]. When we compare two groups of women, aged 20 and
aged 60, they have a baseline incidence of thrombosis of 0.25
per 1000 per year, and 1.60 per 1000 per year, respectively. So,
when they start using hormones, the postmenopausal hor-
mones will cause an excess of cases (1.6 per 1000) that is twice
as large as for oral contraceptive use (0.75 per 1000). This
implies that if efforts were aimed at preventing as many events
of thrombosis as possible, they should be targeted at risk
factors in the elderly.
While age is the strongest determinant of the risk of a first
event of thrombosis, it is unclear why it is such a strong risk
factor. Explanations that have been offered are more immo-
bility, and presence of other or more risk factors and diseases
than in young individuals, as well as decreased muscular tone
and aging of the veins themselves, and particularly of the
valves. It is likely that all of these contribute.
The case-fatality rate of thrombosis was, over 1 month,
6.4% in the Norwegian study of patients of all ages, and nearly
double that rate, at 11% in the US cohort of middle-aged and
elderly individuals [13,14]. Treatment of thrombosis is more
hazardous in old than in young individuals: the risk of major
hemorrhage during anticoagulation increases by nearly 50%
for every decade of age [25].
Genetic risk factors for venous thrombosis
Causes of venous thrombosis are usually divided into environ-
mental and genetic factors, of which the former includes both
factors leading to stasis (surgery, immobilization, plaster casts,
pregnancy) and to hypercoagulability (female hormones, lupus
anticoagulants, malignancies) and the latter almost exclusively
refers to a hypercoagulable state because of abnormalities in
the coagulation system, such as deficiencies of natural antico-
agulants [26,27]. Table 2 lists the risk factors for venous
thrombosis.
Although familial thrombophilia had been recognized much
earlier, the first family with an identified cause (i.e. antithrom-
bin deficiency) was described in 1965 by Egeberg [28].
Deficiencies of protein C and protein S were recognized as
causes of heritable venous thrombosis in the 1980s [29,30].
These deficiencies are found in <1% of the population
(antithrombin deficiency in only one per 5000) [31–33]. Even
though they are strong risk factors for thrombosis, they are so
rare that they are only found in a small percentage of patients
with venous thrombosis [34–38]. Most of the information on
Table 1 Incidence of first venous thrombosis in the elderly (65 + years)
Country Design Person-years Cases (n) Incidence (10)3 year)1) CI95 (10)3 year)1)
France [12] Population 55 015 194 3.5 3.0–4.1
USA [17] Cohort 30 318 85 2.8 2.2–3.4
Norway [14] Population 119 052 488 4.1 3.7–4.5
CI95, 95% confidence interval.
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these deficiencies stems from family studies and not from
population-based studies. As it has been shown that an
individual from a thrombophilic family with an identified
thrombophilic defect has a higher thrombotic risk than an
individual with the same defect but without a family history of
thrombosis, probably because of unknown interacting factors,
the data from family studies cannot be extrapolated to all
carriers of these deficiencies [39]. In a large multicenter cohort
study of familial thrombophilia (European Prospective Cohort
on Thrombophilia, EPCOT), in which 575 asymptomatic
individuals from such families were followed for nearly 6 years,
the annual rate of venous thrombosis was 8 per 1000 (highest,
at 17 per 1000, in antithrombin deficiency), without a clear age-
effect [40]. In two retrospective family studies of antithrombin
deficiency [38] and protein C deficiency [36], the incidence
appeared to be slightly higher among those aged 45 years and
older, at 1–2% per year.
While the deficiencies of natural anticoagulants are rare,
factor (F) V Leiden (G1691A) and prothrombin G20210A are
common variants with an overall incidence of carriers of 2–5%
among Caucasians [41–44]. They are found in 6–20% of
patients with deep vein thrombosis [42,45–47]. Both abnor-
malities increase the risk of thrombosis 3- to 8-fold [42,47], FV
Leiden because it leads to APC-resistance and prothrombin
20210A because it is associated with elevated levels of
prothrombin [42,48]. In the LITE (Longitudinal Investigation
of Thromboembolism Etiology) study, which combines the
data from the Atherosclerosis Risk in Communities (ARIC)
study and Cardiovascular Health Study (CHS), the absolute
risk of thrombosis was investigated for carriers of FVLeiden of
different ages. The ARIC included individuals aged 45–
64 years at baseline, and the CHS included individuals aged
65 and older. In a nested case–control analysis, FV Leiden led
to a 4.6-fold increased risk (vs. non-carriers) in theARIC study,
and a 2.2-fold increased risk in the individuals aged 65 and
older from the CHS 49. In a sub-study of theMEGA study, we
included 238 patients aged over 70 with a first deep vein
thrombosis or pulmonary embolism, and 112 partner controls
who provided a DNA sample. Factor V Leiden or prothrom-
bin 20210A was found in 31 patients (13%) and seven controls
(6%), yielding an odds ratio of 2.2 (CI95: 0.9–6.2).
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Fig. 1. Incidence of first venous thrombosis (deep-vein thrombosis and
pulmonary embolism) by age and sex [14]. Rates are shown per 1000
per year, for men in striped bars, for women in closed bars.
Table 2 Risk factors for venous thrombosis
Acquired Inherited Mixed/unknown
Immobilization Antithrombin deficiency High levels of factor VIII
Plaster cast Protein C deficiency High levels of factor IX
Trauma Protein S deficiency High levels of factor XI
Major surgery Factor V Leiden (FVL) High levels of fibrinogen
Orthopedic surgery Prothrombin 20210A High levels of TAFI
Malignancy Dysfibrinogenemia Low levels of TFPI
Oral contraceptives Factor XIII 34Val APC-resistance in the
Hormonal replacement therapy absence of FVL
Antiphospholipid syndrome Hyperhomocysteinemia
Myeloproliferative disorders High levels of PCI (PAI-3)
Polycythemia vera
Obesity
Central venous catheters
(thrombosis of arm)
TAFI, thrombin activatable fibrinolysis inhibitor; TFPI, tissue factor pathway inhibitor; PCI, protein C inhibitor; PAI-3, plasminogen activator
inhibitor-3.
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Fig. 2. Age distribution of patients with venous thrombosis. Percentage
of patients by age group: 20–39 year, 7.5%; 40–59 year, 21.5%; 60–79
year, 45.9%; 80 + , 23.6%.
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Given the exponential increase of the thrombosis incidence
by age, these data indicate that FV Leiden will lead to a
substantial number of cases of thrombosis in the elderly. A
recent prospective follow-up study within families with pro-
thrombin 20210A found a low risk of venous thrombosis in
asymptomatic carriers (3.7 per 1000 per year), but three out of
four events occurred in individuals aged 50 years and older,
suggesting that this mutation does also increase risk in older
individuals [50].
It has been shown that elevated levels of procoagulant
factors (i.e. fibrinogen, prothrombin (FII), FVIII, FIX and
FXI) as well as of thrombin activatable fibrinolysis inhibitor
(TAFI), are associated with the risk of thrombosis [42,51–55].
Levels that are among the highest 10% of the population
distribution (90th percentile) lead to a 2- to 3-fold increased risk
of venous thrombosis. It is likely that high levels are, at least in
part, genetically determined, which has been demonstrated for
prothrombin levels (prothrombin 20210A), and FVIII levels
(ABO blood group, as well as evidence of unidentified genetic
factors) [42,51,56,57]. Mild hyperhomocysteinemia (over
18 lmol L)1), which is found in 5–10% of the population,
also leads to a 2-fold increased risk of venous thrombosis, by an
unknown mechanism [58–60]. Many coagulation factor levels,
as well as plasma concentrations of homocysteine, increase
with age [61]. Data from the CHS indicate that elevated levels
of coagulation factors remain a determinant of venous
thrombosis in the elderly: high levels of FV antigen (> 75th
percentile) doubled the risk of thrombosis compared with those
in the lowest quintile [62], individuals with the highest levels of
FVIII (> 95th percentile, 195 U dL–1) had a 3-fold increased
risk compared with those with the lowest levels (< 25th
percentile, 100 U dL)1), while a 1.6-fold increased risk was
found for those with FVII levels in the highest 5% of the
distribution (170 U dL)1) vs. those with normal levels
(< 100 U dL)1) [63]. In the same study, D-dimer levels proved
a strong predictor of venous thrombosis, particularly in the
oldest individuals [64]. In the Leiden Thrombophilia Study, a
high level of fibrinogen was a risk factor for thrombosis mainly
in the elderly [55].
Although data on hypercoagulability in the elderly are
scarce, the available reports indicate that abnormalities in the
coagulation system increase the risk of venous thrombosis in
the elderly as they do in young and middle-aged individuals.
Because of the high incidence of high levels of procoagulant
factors among the elderly, these are likely to be major
contributors to the occurrence of venous thrombosis in these
individuals.
Environmental causes of venous thrombosis
Both surgery and major trauma are strong risk factors for
thrombosis. In the absence of thromboprophylaxis, orthopedic
surgery of the hip and knee may lead to thrombosis in up to 30
to 50%of patients [65,66]. Nearly similar risks are conferred by
abdominal surgery, gynecologic surgery and urologic surgery
(in particular open prostatectomy) [67–69]. Multiple trauma,
particularly when including head trauma, spinal injury, pelvic
fractures, femoral fractures and tibial fractures, may cause
thrombosis in up to half of the patients [70–72].
Nowadays, these high frequencies of thrombosis in these
circumstances no longer occur because of the routine use of
anticoagulant prophylaxis. Nevertheless, surgery and trauma
are such strong risk factors that even with anticoagulant
treatment total hip or knee replacement lead to symptomatic
venous thrombosis in 1–3% of patients [73]. Therefore, surgery
remains a major cause of venous thrombosis. In the 1990s we
observed in the Leiden region, where extended anticoagulant
prophylaxis is routinely described for most surgical interven-
tions, that 18% of cases of thrombosis were precipitated by a
surgical intervention, and these interventions were associated
with a 6-fold increased risk of venous thrombosis [74]. In a
recent analysis, over the period 1999–2004, including over 4000
patients with a first venous thrombosis and a similar number of
controls, major surgery and orthopedic surgery still led to a 4-
fold increased risk of symptomatic thrombosis [75].
Immobilization, either because of paralysis, bed rest, plaster
casts or prolonged travel, leads to an increased risk of
thrombosis [76–78]. Immobilization of the lower extremities
interferes with the function of the calf musculature, in
conjunction with the venous valves, of pumping the blood
upstream against gravity. The risk is higher for seated than for
supine immobilization. In London during World War II, the
risk of pulmonary embolism was increased 6-fold shortly after
air raids, during which people sought shelter in the under-
ground where they waited in deckchairs. The risk went down
after the chairs had been replaced by beds [79]. Prolonged
travel increases the risk of thrombosis 2- to 3-fold, particularly
for those with prothrombotic mutations or who are obese [80].
Overall, the risk remains low, at one per 4500 air travellers [81].
It is likely that many of these factors play a major role in
thrombosis in the elderly, as immobilization because of medical
conditions is frequent. In the RIETE registry of patients aged
over 80 with venous thrombosis it was found that they often
had been immobilized for more than 4 days, often had chronic
obstructive lung disease and often had heart failure [82].
Cancer
In 1865, Armand Trousseau observed the strong association
between cancer and venous thrombosis [8] and lent his name to
the Trousseau syndrome (i.e. recurrent thrombophlebitis at
various and changing locations (saltans et migrans) indicating
occult cancer, notably of the pancreas).
Cancermay cause thrombosis because of thrombogenicity of
the tumor itself, for which recent research points to a role of
tissue-factor loaded microparticles [83,84]. Large tumors may
compress veins and cause thrombosis [85,86]. Furthermore, the
disease may lead to weakness and immobility, and the
treatment may be thrombogenic, with an overall 2-fold
increased risk following chemotherapy vs. other therapies
[87–89]. Central venous catheters to administer chemothera-
peutics are the most important cause of thrombosis of the arm
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[90], and over 10% of patients with a central venous catheter
develop symptomatic venous thrombosis of the upper extrem-
ity [91]. Prothrombotic abnormalities, such as FV Leiden and
prothrombin 20210A enhance this risk [92].
Adenocarcinomas confer a 3-fold higher risk of thrombosis
than other types of cancer [93]. The highest risk of thrombosis
is found for pancreatic cancer, with an annualized risk over
10% [94]. Overall, cancer increases the risk of thrombosis
seven-fold, with the highest risk in the first months after
diagnosis (more than 50-fold increased in first 3 months
compared with individuals without cancer), and for those with
distant metastases (20-fold increased vs. those without cancer)
and for carriers of prothrombotic mutations (12-fold increased
compared with those without cancer and such mutations) [95].
Because cancer is such a strong risk factor for thrombosis, a
substantial number of patients who present with thrombosis
have cancer, in some cases still undiagnosed. It has been
estimated that between 5% and 20% of patients who present
with thrombosis have cancer, with the highest prevalence
among those with idiopathic thrombosis, of whom a substan-
tial proportion (several per cent) is diagnosed with cancer in the
year after the thrombosis [92,96–98]. Cancer is a major
contributor to the high case–fatality rate of venous thrombosis
[13,14].
In the RIETE registry of very old patients with venous
thrombosis, cancer was present in 18% of patients aged over
80, which was not much different from its prevalence in
younger patients [82], although higher than in the MEGA
study, where 12% of patients (who were all aged under 70,
mean age 50) had ever been diagnosed with cancer prior to the
thrombotic event [95].
When we analyzed the participants in a sub-study of the
MEGA study aged 70 years and older on whom we had
information on cancer, 36 (12.5%) out of 287 cases and 11
(7.7%) out of 142 controls had been diagnosed with cancer
in the 5 years preceding the index date (date of thrombosis
diagnosis in cases, and a similar date in controls), yielding
an odds ratio of 1.7 (CI95, 0.8–3.7). On a relative scale, this
is substantially lower than the relative risk for patients
under 70 in the same study (cancer diagnosed in 5 years
prior to the index date: OR = 6.6). Even on an absolute
scale, when we take into account that the baseline risk of
venous thrombosis is around one per 1000 per year in those
aged 50, and five per 1000 per year in those aged over 70
(Fig. 1), cancer appears less of a risk factor in old age than
at younger ages. Although the prevalence of malignancies is
high at advanced age, the odds ratio of 1.7 combined with
the prevalence of 7.7% of a recent diagnosis with cancer
predicts that only 5% of all venous thrombotic events in the
elderly can be attributed to cancer (population attributable
risk, PAR).
Hormonal replacement therapy
Estrogens relieve symptoms of menopause, and prolonged
treatment reduces the progression of osteoporosis [99–101].
However, hot flushes also often disappear without active
treatment [102], and it is unclear whether hormone therapy
prevents fractures [103,104]. Hormone use has no beneficial
effect on arterial disease and increases the risk of breast cancer
[103,105].Many studies have shown that hormone replacement
therapy increases the risk of venous thrombosis 2- to 4-fold
[21–24,106–110]. A recent study has suggested that estrogens
administered by transdermal patches, that eliminate a first-pass
effect through the liver, do not increase the risk of thrombosis
[111], although previous reports did find an increased risk for
patches [106,107].
Most studies on oral preparations concern equine conju-
gated estrogens. In a recent large case–control study of 586
postmenopausal women with venous thrombosis and 2268
controls, a 1.7-fold increased risk was observed for users of
conjugated estrogens, while no excess risk was present for users
of esterified estrogens [112]. The risk of venous thrombosis in
hormone users is particularly high in those who are obese and
have APC-resistance because of FV Leiden [24,113–115]. The
absence of an increased risk of users of esterified estrogens was
mainly visible in the absence of this synergistic effect with
prothrombotic mutations [116]. This was in line with a
subsequent study of the effect of various types of postmeno-
pausal hormones on the coagulation system in healthy users,
where an acquired APC-resistance was observed in users of
conjugated estrogens, but not of esterified estrogens [117].
Conclusion
Venous thrombosis is a common disorder in the elderly with a
substantial morbidity and mortality. Environmental risk fac-
tors, particularly immobilization, play an important role in the
etiology of thrombosis in the elderly, and cause a substantial
proportion of the total number of cases because risk factors
associated with disease are more prevalent in old than in young
individuals. Abnormalities in the clotting system, either genetic
or acquired, appear to be equally and possibly more important
in the elderly than in young and middle-aged individuals.
Therefore, thrombosis in the elderly should be a focus of future
studies.
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